Lyka Labs Limited
Corporate Office : Ground Floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036.
Phone : 022 6611 2200 / 244 /290 • Website : www.lykalabs.com • Email : enquiry@lykalabs.com
LYKA
Healthcare through Innovation

1st August, 2025

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Script Code: 500259

National Stock Exchange of India Limited
Exchange Plaza, G. Block, Bandra Kurla
Complex, Bandra (East),
Mumbai - 400 051

Script Code: LYKALABS

Dear Sir/Madam,

Sub: Outcome of the Board Meeting – 1st August, 2025

Ref: Intimation under Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the SEBI Listing Regulations)

We are pleased to inform you that the Board of Directors of the Company in its meeting held today i.e. 1st August, 2025, has *inter-alia*, considered and approved and taken on record the following:

Financial Results

Unaudited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2025 alongwith Limited Review Report thereon is enclosed herewith as **Annexure -1**.

Resignation of Company Secretary

The Board took note of the resignation tendered by Mr. Shekhar R Singh as a Company Secretary and Compliance Officer vide letter dated 1st July, 2025 citing the reason to pursue an alternative career opportunity outside the organization. The resignation was effective from the close of business hours on 30th July, 2025. Mr. Shekhar R Singh has confirmed that he will continue to discharge all responsibilities, including those connected with the forthcoming 46th Annual General Meeting (AGM) and will ensure a smooth, structured handover before his exit.

After due consideration, the Board accepted the resignation with effect from the close of business hours on Friday, the 1st August, 2025 and placed on record its appreciation for the valuable contributions made by Mr. Shekhar R Singh during his tenure with the Company.

Appointment of Internal Auditors

Approved the appointment of Sudit K Parekh & Co. LLP, Chartered Accountants (Firm Registration Number: 110512W/ W100378), as an Internal Auditor of the Company for the financial year 2025-26.

The brief details of the aforesaid changes (resignation and appointment) as prescribed under SEBI Listing Regulations read with SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024, are enclosed as an **Annexures – 2 and 3.**

These are also being made available on the website of the Company at www.lykalabs.com . The meeting of the Board of Directors commenced at 11:10 am and concluded at 12:25 pm

Kindly take the same on your record.

Thanking you,

Yours faithfully,
For **Lyka Labs Limited**

SHEKHAR RAMJEET SINGH

Digitally signed by SHEKHAR RAMJEET SINGH
Date: 2025.08.01 12:27:56 +05'30'

Shekhar R Singh
Company Secretary

Encl.: as above

Lyka Labs Limited

Corporate Office : Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036
• Phone : 6611 2200/290 Website : www.lykalabs.com • Email : enquiry@lykalabs.com

LYKA
Healthcare Through Innovation

Statement of Standalone Unaudited Financial Results for the Quarter Ended 30th June, 2025

(₹ in lakhs)

	Particulars	Quarter Ended			Year Ended
		June-25 (Unaudited)	March-25 (Audited)	June-24 (Unaudited)	March-25 (Audited)
I	**Revenue**				
	Revenue from Operations	2917.64	3051.65	3010.47	13469.74
	Other Income	66.67	72.04	61.95	234.35
II	**Total Income**	**2984.31**	**3123.68**	**3072.42**	**13704.09**
III	**Expenses**				
(a)	Cost of Materials Consumed	804.94	967.54	777.53	3707.18
(b)	Purchase of Stock in trade	224.86	210.27	400.09	1752.37
(c)	Change in inventories of Finished Goods, work-in-progress and stock-in-trade	15.97	(58.55)	(28.09)	(137.31)
(d)	Employee benefits expense	897.40	951.63	803.50	3409.02
(e)	Finance Costs	85.10	52.03	65.07	230.45
(f)	Depreciation and amortisation expense	203.36	133.83	167.70	645.31
(g)	Other expenses	635.59	639.80	652.05	2949.60
	Total Expenses	**2867.22**	**2896.54**	**2837.85**	**12556.62**
IV	**Profit / (Loss) before Exceptional Items and Taxes (II - III)**	**117.09**	**227.14**	**234.57**	**1147.47**
V	**Exceptional Items (Net)**	0.00	0.00	0.00	0.00
VI	**Profit / (Loss) before Tax**	**117.09**	**227.14**	**234.57**	**1147.47**
VII	**Tax Expenses**				
	Current Tax	31.00	62.00	40.00	272.41
	Deferred Tax	4.67	34.52	19.61	52.34
VIII	**Net Profit / (Loss) after Tax**	**81.42**	**130.62**	**174.96**	**822.72**
IX	**Other Comprehensive Income (Net of Tax) - Net Credit / (Charge)**	0.00	18.22	0.00	18.22
X	**Total Comprehensive Income / (Loss)**	**81.42**	**148.84**	**174.97**	**840.94**
	Paid up Equity Share Capital (FV ₹ 10/- each)	3569.00	3569.00	3569.00	3569.00
	Other Equity				9925.09
XI	**Basic and diluted earnings per share**	0.22	0.36	0.49	2.28

Notes:

1.The above unaudited standalone financial results were considered by the Audit Committee in its meeting, which was approved and taken on record at the meeting of the Board of Directors; held on 01st August 2025

2. The Company operates in one business segment i.e. "Pharmaceuticals".

3. The figures for the previous year have been regrouped / rearranged wherever considered necessary.

4. The Statutory Auditors have expressed an unqualified opinion on the Unaudited Standalone financials results for the quarter ended 30th June, 2025.

For **Lyka Labs Limited**

LYKA LABS LIMITED MUMBAI

Kunal Gandhi
Managing Director & CEO
DIN: 01516156

Mumbai : 01st August 2025

INDIA

D. KOTHARY & CO.
Chartered Accountants

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Lyka Labs Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Lyka Labs Limited** (the "Company") for the quarter ended June 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with Standards of Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. Kothary & Co.
Chartered Accountants
Firm Registration No. 105335W

Deepak O. Narsaria
(Partner)
Membership No. 121190
UDIN: 25121190BMLLXR1483

D. KOTHARY & CO. MUMBAI CHARTERED ACCOUNTANTS

Place: Mumbai
Date: 1st August, 2025

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Lyka Labs Limited

1. We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of **Lyka Labs Limited** (the "Parent"), which includes its subsidiary (the Parent and its subsidiary together referred to as "the Group"), for the quarter ended June 30, 2025 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

4. The Statement includes the results of following entities:
   Subsidiaries
   i) Lyka BDR International Limited
   ii) Lyka Exports Limited

5. The accompanying statement includes the interim financial results and other financial information in respect of 2 subsidiaries, whose interim financial results/information reflects total revenues of Rs. 498.43 lakhs, total net profit/ (loss) after tax of Rs. 18.21 lakhs for the quarter ended June 30, 2025, total comprehensive income of Rs. 18.21 lakhs which have been reviewed by us.

D. KOTHARY & CO. * MUMBAI * CHARTERED ACCOUNTANTS

6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. Kothary & Co.
Chartered Accountants
Firm Registration No. 105335W

Deepak O. Narsaria
(Partner)
Membership No. 121190

UDIN: 25121190BMLLXS7530

Place: Mumbai
Date: 1st August, 2025

D. KOTHARY & CO. * CHARTERED ACCOUNTANTS * MUMBAI

Lyka Labs Limited

Corporate Office : Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036
• Phone : 6611 2200/290 Website : www.lykalabs.com • Email : enquiry@lykalabs.com

LYKA
Healthcare Through Innovation

Statement of Consolidated Unaudited Financial Results for the Quarter Ended 30th June 2025

(₹ in lakhs)

	Particulars	Quarter Ended			Year Ended
		Jun-25	Mar-25	Jun-24	Mar-25
		(unaudited)	(Audited)	(unaudited)	(Audited)
I	**Revenue**				
	Revenue from Operations	3,302.54	3,342.87	3,011.40	13,849.54
	Other Income	63.09	82.01	55.88	223.17
II	**Total Income**	**3,365.63**	**3,424.88**	**3,067.28**	**14,072.71**
III	**Expenses**				
(a)	Cost of Materials Consumed	804.94	967.54	777.53	3,707.18
(b)	Purchase of Stock in trade	453.00	398.13	400.75	1,987.95
(c)	Change in inventories of finished goods, work-in-progress and stock-in-trade	15.89	(57.20)	(28.09)	(135.96)
(d)	Employee benefits expense	904.84	961.12	818.77	3,463.26
(e)	Finance Costs	85.38	46.81	64.71	227.25
(f)	Depreciation and amortisation expense	211.18	141.66	175.66	676.93
(g)	Other expenses	755.23	665.03	671.70	3,033.61
	Total Expenses	**3,230.46**	**3,123.10**	**2,881.03**	**12,960.22**
IV	**Profit / (Loss) before Exceptional Items and Taxes (II - III)**	**135.17**	**301.79**	**186.25**	**1,112.49**
V	**Exceptional Items (Net)**	-	-	-	-
VI	**Profit / (Loss) before Tax**	**135.17**	**301.79**	**186.25**	**1,112.49**
VII	**Tax Expenses**				
	Current Tax / Earlier Year Tax	31.00	62.00	40.00	272.65
	Deferred Tax	4.55	36.94	17.30	46.52
VIII	**Net Profit / (Loss) after Tax**	**99.62**	**202.85**	**128.95**	**793.32**
IX	**Other Comprehensive Income**	-	18.09	(0.34)	18.09
X	**Total Comprehensive Income / (Loss)**	**99.62**	**220.94**	**128.61**	**811.41**
XI	**Profit After Tax Attributed to**				
	Owners of the Parent	93.26	177.15	143.91	801.20
	Non-controlling Interest	6.36	25.70	(14.97)	(7.88)
		99.62	**202.85**	**128.94**	**793.32**
XII	**Other Comprehensive Income**				
	Owners of the Parent	-	18.14	(0.25)	18.14
	Non-controlling Interest	-	(0.05)	(0.09)	(0.05)
		-	**18.09**	**(0.34)**	**18.09**
XIII	**Total Comprehensive Income / (Loss)**				
	Owners of the Parent	93.26	195.29	143.67	819.34
	Non-controlling Interest	6.36	25.65	(15.05)	(7.93)
		99.62	**220.94**	**128.62**	**811.41**
XIV	Paid up Equity Share Capital (FV Rs.10/- each)	3,569.00	3,569.00	3,569.00	3,569.00
	Other Equity				6,786.02
XV	**Basic and diluted earnings per share**	0.25	0.49	0.40	2.22

LYKA LABS LIMITED MUMBAI

Regd. Office : 4801 / B & 4802 / A, G.I.D.C. Industrial Estate, Ankleshwar - 393 002.
• Phone : 02646 221422 / 220549 • Fax : 02640-250692
CIN L24230GJ1976PLC008738

Lyka Labs Limited

Corporate Office : Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036
• Phone : 6611 2200/290 Website : www.lykalabs.com • Email : enquiry@lykalabs.com

LYKA
Healthcare Through Innovation

Notes:

1.The above Unaudited consolidated financial results were considered by the Audit Committee in its meeting, which was approved and taken on record at the meeting of the Board of Directors; held on 1st August 2025

2.The Company operates in one business segment i.e. "Pharmaceuticals".

3. The figures for the previous year have been regrouped / rearranged wherever considered necessary.

4.During the reporting period, Lyka BDR International Ltd, a subsidiary of the Company, has written off a claim amounting to Rs. 68.48 lakhs due to a product quality, the said goods supplied in the earlier year.

5. The Statutory Auditors have expressed an unqualified opinion on the Unaudited Consolidated financials results for the quarter 30th June 2025

LYKA LABS LIMITED MUMBAI

For **Lyka Labs Limited**

Kunal Gandhi
Managing Director & CEO
DIN: 01516156

Mumbai: 1st August 2025

Regd. Office : 4801 / B & 4802 / A, G.I.D.C. Industrial Estate, Ankleshwar - 393 002.
• Phone : 02646 221422 / 220549 • Fax : 02640-250692
CIN L24230GJ1976PLC008738

Annexure - 2

Resignation of Company Secretary

Details of the events	Information of the events
The reason for change viz. appointment, resignation, removal, death or otherwise	Resignation of Shekhar R Singh as a Company Secretary of the Company
Date of Cessation	The resignation was effective from the close of business hours on 30th July, 2025. Mr. Shekhar R Singh has confirmed that he will continue to discharge all responsibilities, including those connected with the forthcoming 46th Annual General Meeting (AGM).
Brief profile	Not applicable
Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

Resignation Letter

From:
Shekhar R Singh

1st July, 2025

To
The Board of Directors
Lyka Labs Limited
Spencer Building, 30, Forjett Street,
Grant Road (West),
Mumbai - 400007

Dear Sir/Madam,

Sub.: Resignation as the Company Secretary (Key Managerial Personnel), Compliance Officer and Nodal Officer of the Company

I hereby resign from the position of Company Secretary (Key Managerial Personnel), Compliance Officer and Nodal Officer of the Company to pursue an alternate career opportunity outside the organisation.

This decision has been made after careful consideration of my personal and professional aspirations. I confirm that there is no other material reason for my resignation apart from this.

I respectfully request the Board to take my resignation on record and to relieve me from my duties with effect from the close of business hours on Wednesday, the 30th July, 2025, after completion of my notice period.

During the notice period, I remain committed to ensuring a smooth and seamless transition, including the proper handover of my responsibilities to my successor. I will extend my full co-operation throughout the process.

I further request the Company to file the necessary forms with the Registrar of Companies, Ministry of Corporate Affairs, and to intimate the Stock Exchanges, as applicable, to give effect to this resignation.

I take this opportunity to express my sincere gratitude to the Board, Senior Management, and all colleagues of the Company for the trust, support, and professional growth I have experienced during my tenure.

Thanking you,

Yours faithfully,

Shekhar

Shekhar R Singh
Membership: FCS -12881

Annexure - 3

Appointment of Internal Auditor

Details of the events	Information of the events
The reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of Sudit K Parekh & Co. LLP, Chartered Accountants (Firm Registration Number: 110512W/ W100378) as an Internal Auditor of the Company.
Date of appointment	1st August, 2025 ▪ For conducting Internal Audit of the Company for the Financial Year 2025-26
Term of appointment	For financial year 2025-26
Brief profile	Sudit K Parekh & Co. LLP, is a firm of practicing Chartered Accountants based in Mumbai offering a wide spectrum of Services to its esteemed clientele. The firm has handled various assignments in internal audit. The Firm has highly qualified Partners and an experienced team.
Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable.